| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Miller Aine | SVP, DEV & HEAD OF IRE OFFICE | C/O THERAVANCE BIOPHARMA US, LLC, 901 GATEWAY BLVD, SOUTH SAN FRANCISCO | /s/ Brett A Grimaud, Attorney-in-Fact | 24 Feb 2026 | 0002012524 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TBPH | Ordinary Shares | Tax liability | $331,291 | -16,851 | -8.4% | $19.66 | 184,161 | 20 Feb 2026 | Direct | F1 |
| Id | Content |
|---|---|
| F1 | Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. |